Competitive landscape
Drugs aimed at the same indication, from approved to preclinical.
1 drug for “Higher-risk Myelodysplastic Syndrome”
Phase 3 1
- LisaftoclaxASCENTAGE PHARMA GROUP INTERNATIONALHigher-risk Myelodysplastic Syndrome
Drugs whose recorded indications name this term, by development stage. Indications come from registries and labels, so a drug can appear under related terms.